



General Assembly

Amendment

January Session, 2007

LCO No. 8657

SB0103308657SD0

Offered by:

SEN. HANDLEY, 4th Dist.
REP. SAYERS, 60th Dist.
REP. DREW, 132nd Dist.
SEN. MCKINNEY, 28th Dist.
REP. MILLER, 122nd Dist.
REP. KEHOE, 31st Dist.
REP. PERONE, 137th Dist.

REP. LEWIS, 8th Dist.
REP. MORRIS, 140th Dist.
REP. MCMAHON, 15th Dist.
REP. MIOLI, 136th Dist.
REP. FAWCETT, 133rd Dist.
REP. RITTER, 38th Dist.
REP. OLSON, 46th Dist.

To: Subst. Senate Bill No. 1033

File No. 108

Cal. No. 155

**"AN ACT PROVIDING RESOURCES FOR EARLY DETECTION,
DIAGNOSIS AND TREATMENT OF LUNG CANCER."**

1 Strike everything after the enacting clause and substitute the
2 following in lieu thereof:

3 "Section 1. (NEW) (*Effective October 1, 2007*) (a) Subject to the
4 provisions of subsection (b) of this section, each individual health
5 insurance policy providing coverage of the type specified in
6 subdivisions (1), (2), (4), (11) and (12) of section 38a-469 of the general
7 statutes delivered, issued for delivery, amended, renewed or
8 continued in this state on or after October 1, 2007, shall provide
9 coverage for expenses arising from human leukocyte antigen testing,
10 also referred to as histocompatibility locus antigen testing, for A, B and

11 DR antigens for utilization in bone marrow transplantation.

12 (b) Such policy may:

13 (1) Require that such testing be performed in a facility (A)
14 accredited by the American Association of Blood Banks, or its
15 successor, or the College of American Pathologists, or its successor, or
16 any other national accrediting body with requirements that are
17 substantially equivalent to or more stringent than those of the College
18 of American Pathologists, and (B) certified under the Clinical
19 Laboratory Improvement Act of 1967, 42 USC Section 263a, as from
20 time to time amended;

21 (2) Limit coverage to individuals who, at the time of such testing,
22 complete and sign an informed consent form that also authorizes the
23 results of the test to be used for participation in the National Marrow
24 Donor Program; and

25 (3) Limit such coverage to a lifetime maximum benefit of one
26 testing.

27 Sec. 2. (NEW) (*Effective October 1, 2007*) (a) Subject to the provisions
28 of subsection (b) of this section, each group health insurance policy
29 providing coverage of the type specified in subdivisions (1), (2), (4),
30 (11) and (12) of section 38a-469 of the general statutes delivered, issued
31 for delivery, amended, renewed or continued in this state on or after
32 October 1, 2007, shall provide coverage for expenses arising from
33 human leukocyte antigen testing, also referred to as histocompatibility
34 locus antigen testing, for A, B and DR antigens for utilization in bone
35 marrow transplantation.

36 (b) Such policy may:

37 (1) Require that such testing be performed in a facility (A)
38 accredited by the American Association of Blood Banks, or its
39 successor, or the College of American Pathologists, or its successor, or
40 any other national accrediting body with requirements that are

41 substantially equivalent to or more stringent than those of the College
 42 of American Pathologists, and (B) certified under the Clinical
 43 Laboratory Improvement Act of 1967, 42 USC Section 263a, as from
 44 time to time amended; and

45 (2) Limit coverage to individuals who, at the time of such testing,
 46 complete and sign an informed consent form that also authorizes the
 47 results of the test to be used for participation in the National Marrow
 48 Donor Program; and

49 (3) Limit such coverage to a lifetime maximum benefit of one
 50 testing."

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>October 1, 2007</i>	New section
Sec. 2	<i>October 1, 2007</i>	New section